The interaction of the prostaglandin E derivative rioprostil with oral anticoagulant agents

Pharmacokinetic drug interactions with anti-ulcer drugs

The safety profile of any pharmacological agent is defined on the basis of its toxicity, tolerability and potential for pharmacokinetic and/or pharmacodynamic interactions with other compounds, which may belong to the same or to a different pharmacological class. Drug-drug interactions are important in clinical practice because short and long term therapeutic regimens frequently require coadministration of different drugs. The pharmacological treatment of gastric and duodenal ulcers (and of related syndromes) includes older and newer compounds, which have different mechanisms of action and exert different therapeutic effects. These compounds are widely prescribed in combination with other drugs being given for the treatment of concomitant diseases. This article reviews pharmacokinetic interactions with anti-ulcer drugs, paying particular attention to those which have clinically relevant adverse effects. Drugs mentioned in the literature as causing any pharmacokinetic interaction with anti-ulcer compounds are considered in this article.

Lack of effect of ponsinomycin on the pharmacokinetics of nicoumalone enantiomers

Pharmacokinetic interaction between ponsinomycin-nicoumalone was studied in six subjects who received an 8 mg oral dose of racemic nicoumalone alone and 4 days into an oral regimen of ponsinomycin 800 mg twice daily. The concentrations of R(+) and S(-)-nicoumalone in plasma were measured using a stereospecific h.p.l.c. assay. The disposition characteristics of nicoumalone enantiomers in the control phase of this study were similar to those reported previously with the exception of the data for one subject whose oral clearance for S(-)-nicoumalone was seven times lower than those in the other subjects. A statistically significant effect of ponsinomycin on the kinetics of R(+) and S(-)-nicoumalone was not demonstrated.